MedCity News October 27, 2024
Seaport Therapeutics’ Series B financing was one of the largest rounds of funding in our recap of biotech financing news, which spans startups developing drugs for neurological diseases, cancer, immunology, and more.
Six months after launching with a mega-round of financing, Seaport Therapeutics has raised $225 million more to advance a lead drug candidate that could overcome some limitations of currently available treatments for depression.
Seaport’s platform technology, called Glyph, designs oral drugs that leverage the lymphatic system to deliver the medicine in a way that makes more of the active pharmaceutical ingredient available in the body to confer its therapeutic effect. The Boston-based company also says its drugs reduce complications such as elevated liver enzyme levels, a sign of...
Today's Sponsors
Today's Sponsor